Spark Investment Management’s Standard BioTools LAB Stock Holding History

Spark Investment Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14,200	Closed	-$105K	–	60
2020 Q3	$105K	Hold	14,200	–	–	0.15%	42
2020 Q2	$56K	Sell	14,200 -61,600	-81%	-$215K	0.21%	56
2020 Q1	$192K	Buy	75,800 +39,600	+109%	+$130K	0.1%	233
2019 Q4	$125K	Buy	+36,200	New	+$127K	0.01%	489
2019 Q1	–	Sell	-179,100	Closed	-$1.54M	–	682
2018 Q4	$1.54M	Buy	179,100 +166,100	+1,278%	+$1.29M	0.11%	245
2018 Q3	$97K	Buy	+13,000	New	+$92.4K	0.01%	611
2018 Q2	–	Sell	-12,500	Closed	-$73K	–	693
2018 Q1	$73K	Buy	12,500 +1,000	+9%	+$6.57K	﹤0.01%	566
2017 Q4	$67K	Buy	+11,500	New	+$63K	﹤0.01%	647
2014 Q2	–	Sell	-7,800	Closed	-$343K	–	690
2014 Q1	$343K	Buy	+7,800	New	+$343K	0.05%	418

Other funds holding LAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Spark Investment Management's LAB Position: Q4 2020 in Review

Spark Investment Management sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 14,200 shares — an estimated $105K sold.

Spark Investment Management first reported a position in LAB in Q1 2014 and held it in 9 quarters. The position peaked at $1.54M in Q4 2018. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

Spark Investment Management reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
Spark Investment Management sold 14,200 Standard BioTools shares in Q4 2020, an estimated $105K.
Spark Investment Management first reported a position in Standard BioTools in Q1 2014 and held it in 9 quarters.
Spark Investment Management's Standard BioTools position peaked at $1.54M in Q4 2018.
145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Spark Investment Management's 13F filing for Q4 2020, filed 11 Feb 2021.